Edwards Discontinues Centera TAVR Program As Sapien Sales Continue To Climb

Edwards Lifesciences is giving up on the Centera transcatheter aortic valve replacement (TAVR), despite promising clinical results, to focus on its Sapien TAVR line. The company reported overall revenue of $1.1bn in the second quarter of 2019, representing 14% year-over-year growth, driven by 18% growth in sales of Sapien systems.

Rising-graph-line
• Source: shutterstock.com

Edwards Lifesciences Corp. is discontinuing its Centera self-expanding transcatheter aortic valve replacement (TAVR) system to focus entirely on its successful Sapien 3 and Sapien 3 Ultra balloon-expandable TAVR systems.

“While the Centera valve has demonstrated excellent clinical outcomes and is performing well for patients, the time and resources required...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Approvals

More from Policy & Regulation